WKB advised Selvita S.A. on the acquisition of 100% of shares in PozLab sp. z o.o.
Selvita S.A. has successfully signed a preliminary agreement for 100% of shares in PozLab sp. z o.o. – a company acting as an independent research and development laboratory.
PozLab sp. z o.o. provides comprehensive R&D analytical services (chemical and pharmaceutical) to the pharmaceutical, food, cosmetics, veterinary and related industries. In addition, the company offers the development of pharmaceuticals, dietary supplements and cosmetics, from concept to market implementation, and performs comprehensive microbiological analyses.
Selvita S.A. specializes in integrated research and development projects in the area of drug discovery and development that combine the early stage of drug discovery with the clinical trial stage. It is one of the largest contract research organization (CRO) companies in Europe.
WKB lawyers provided comprehensive transactional legal support starting from performing due diligence of the company, structuring the transaction to negotiating and assisting in finalising the transaction documentation. WKB lawyers have also supported Selvita S.A. in negotiating a new long -term lease agreement for continued use of PozLab’s laboratory space.
The M&A team was led by Jakub Jędrzejak, assisted by Sebastian Woźniak, Zuzanna Cybulska and Dorota Gajuk. The negotiations of a lease agreement for laboratory space used by the Company were carried out with the support of Bartosz Łaski and Marta Pałyga.
The value of the transaction is set at PLN 25 million (subject to purchase price adjustment), and the closing of the transaction is subject to the fulfilment of the conditions precedent set out in the agreements.